Clinical analysis of 169 patients with prostate cancer
| Autor: | OKANEYA, Toshikazu, MIZUSAWA, Hiroya, YONEYAMA, Takehisa, TAGUCHI, Isao, KOMIYAMA, Itsuki, KAWAKAMI, Masako, HOSAKA, Kyoko, TSURUTA, Takashi, MURATA, Yasushi, KOMATSU, Hirofumi, MISAWA, Kazumichi, KIYOKAWA, Hideo |
|---|---|
| Jazyk: | japonština |
| Rok vydání: | 1996 |
| Předmět: | |
| Zdroj: | 泌尿器科紀要. 42(8):563-567 |
| ISSN: | 0018-1994 |
| Popis: | 1986年4月からの9年2ヵ月間に前立腺癌と診断された169例の治療結果を示し, 予後因子と患者の年齢がそれらに与える影響について検討した.予後因子として臨床病期と組織学的分化度が重要であるが, 他因死が多いことからは年齢を考慮して治療法を選択することが必要である.今後は早期診断の為のスクリーニングが必要であろう At Matsumoto National Hospital, 169 patients with prostate cancer were diagnosed between April 1986 and May 1994. The prostate cancer incidence was the highest in the latter half of the seventies, with an average age of 74.3 years. The clinical stage was defined as A1, A2, B, C, and D2 in 24 (14.2%), 38 (22.5%), 39 (23.1%), 23 (13.6%) and 45 (26.6%) patients, respectively. The clinical stage was not correlated with the patient's age. Incidental carcinoma was discovered in 5.8% of the patients who underwent prostatectomy for benign prostatic hypertrophy (BPH). At initial diagnosis, the tumor was well, moderately, and poorly differentiated adenocarcinoma in 71 (42.0%), 64 (37.9%), and 34 (20.1%) patients, respectively. The median follow-up period was 38.7 months. The over all five-year crude survival rate was 54.8%, while the cause-specific five-year survival rate was 80.0%. The five-year crude survival rate was 58.4, 82.0, 55.2, 42.5 and 37.4%, for patients with cancer at stage A1, A2, B, C, and D. The survival rate was higher for patients with cancer at clinical stage A and shorter for those with cancer at clinical stage D than in other stages. Prognosis was also worse in patients with moderately or poorly differentiated adenocarcinoma than in those with well-differentiated adenocarcinoma. The clinical stage and the pathological grade are important as prognostic factors, although the high incidence of death from other diseases shows that the patients' age should be considered to choose the modality of therapy. These findings indicate that intensive treatment of the patients in clinical stage A2, B and C prostate cancer in combination with screening for the men between 50 and 75 years old for early cancer detection is required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|